Abstract: A battery assembly can include a pair of batteries. The battery pair may be electrically coupled by a bimetallic strip. When the temperature of the battery assembly exceeds a threshold temperature, the bimetallic strip deforms so that the coupling between the first and second batteries breaks. In other cases, the battery pair may be coupled by a spring-loaded connector. A sacrificial block configured to melt if the temperature of the battery assembly increases beyond the threshold temperature may force the spring into an energy-storing configuration. When the sacrificial block melts, the spring is released, and the connector is forced in a direction away from the battery terminals. Finally, the battery assembly may include a thermopile and one or more relays. When a temperature gradient of the thermopile exceeds a threshold gradient, the thermopile generates a voltage that causes the relays to disconnect the battery assembly from a charging circuit.

Abstract: Described herein are methods of managing series of heterogeneous battery components that can include the steps of: for each of a plurality of terminal sets having one or more adjacent terminals in the series, measuring a respective voltage difference and a respective current draw over a period of time for the terminal set, and calculating a respective normalized parameter value for the terminal set based on the respective voltage difference and the respective current draw for the terminal set; based on normalized parameter values for two or more terminal sets in the series, calculating a statistical measure of the normalized parameter values; determining a switching duty cycle based on the statistical measure; and activating a relay in electrical communication with at least one of the terminal sets in the series using a pulse-width modulated signal having the determined switching duty cycle.

Abstract: The invention relates to improvements relating to cancer therapy based on the identification of a number of regions of CPG2 which contain epitopes which appear to be involved in the production of a host immune response and which may be modified to alter the immunogenicity in patients. Production of fusions of CPG2 with an antibody, where the CPG2 protein has been tagged provides a CPG2 protein which has reduced immunogenicity. By using partially glycosylated enzyme obtainable by P. pastoris expression, the efficacy of antibody-CPG2 fusions is enhanced.

Abstract: The invention relates to improvements relating to cancer therapy based on the identification of a number of regions of CPG2 which contain epitopes which appear to be involved in the production of a host immune response and which may be modified to alter the immunogenicity in patients. Production of fusions of CPG2 with an antibody, where the CPG2 protein has been tagged provides a CPG2 protein which has reduced immunogenicity. By using partially glycosylated enzyme obtainable by P. pastoris expression, the efficacy of antibody-CPG2 fusions is enhanced.

Abstract: A method for treatment of tumors to which antibody A5B7 binds is disclosed. A5B7 is a monoclonal antibody which binds to carcinoembryonic antigen. The method comprises administering to a host in need of such treatment an effective amount of a system which comprises a conjugate comprising: antibody A5B7 or a humanized version of A5B7 linked to an enzyme selected from the group consisting of carboxypeptidase G2 (CPG2), nitroreductase, a human enzyme, a non-human enzyme rendered non-immunogenic in man and a humanized catalytic antibody; and a prodrug convertible under the influence of the conjugate into a cytotoxic drug.

Abstract: A treatment for tumors to which antibody A5B7 binds is disclosed. A5B7 is a monoclonal antibody which binds to carcinoembryonic antigen. The treatment comprises administering to a host in need of such treatment an effective amount of a system which comprises: a conjugate comprising antibody A5B7 or a humanized version of A5B7 linked to an enzyme selected from the group consisting of carboxypeptidase G2 (CPG2), nitroreductase, a human enzyme, a non-human enzyme rendered non-immunogenic in man and a humanized catalytic antibody; and a prodrug convertible under the influence of the conjugate into a cytotoxic drug.